Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.

Infection and Immunity
G H LowellC Colleton

Abstract

Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphylococcal enterotoxin B (SEB) toxoid in saline elicited higher anti-SEB serum immunoglobulin G (IgG) titers when the toxoid was formulated with proteosomes. In addition, intranasal immunization of mice with this proteosome-toxoid vaccine elicited high levels of anti-SEB IgA in lung and intestinal secretions, whereas the toxoid without proteosomes did not. Two i.m. immunizations with proteosome-toxoid plus alum also induced higher murine serum responses than alum-adjuvanted toxoid without proteosomes. Furthermore, proteosome-toxoid delivered intranasally in saline or i.m. with either saline or alum afforded significant protection against lethal SEB challenge in two D-galactosamine-sensitized murine models of SEB intoxication, i.e., the previously described i.m. challenge model and a new respiratory challenge model of mucosal SEB exposure. Efficacy correlated with the induction of high serum levels of anti-SEB IgG. In contrast, intranasal or i.m. immunization with toxoid in saline without proteosomes was not significantly protective in either challenge model. Proteosome-toxoid plus alum given i.m. also elicited more sig...Continue Reading

References

Nov 1, 1975·Infection and Immunity·L SperoW H Adler
Aug 1, 1992·AIDS Research and Human Retroviruses·R Edelman
Jun 24, 1991·Journal of Immunological Methods·C R Alving
Sep 1, 1990·The Journal of Experimental Medicine·Y ChoiB L Kotzin
Jan 1, 1990·International Reviews of Immunology·R Edelman, C O Tacket
May 11, 1990·Science·P Marrack, J Kappler
Feb 1, 1988·The Journal of Experimental Medicine·G H LowellW D Zollinger
Aug 1, 1972·Toxicon : Official Journal of the International Society on Toxinology·W R Beisel
Aug 28, 1973·Biochemistry·P Cuatrecasas
Jun 1, 1965·Biochemistry·E J SchantzM S Bergdoll
May 1, 1993·The Journal of Infectious Diseases·P M Schlievert
May 1, 1992·Trends in Cell Biology·M R Neutra, J P Kraehenbuhl

❮ Previous
Next ❯

Citations

Apr 6, 2007·Expert Review of Vaccines·Dongmei Lu, Anthony J Hickey
Apr 10, 2014·Frontiers in Immunology·Ingrid L ScullyAnnaliesa S Anderson
Mar 14, 2017·Expert Review of Vaccines·Nidhi ChauhanUtkarsh Jain
Nov 28, 2001·Current Infectious Disease Reports·Jean C. Lee
May 14, 2014·BioMed Research International·Laura C HudsonKenneth J Piller
Mar 24, 2010·Infection and Immunity·Mulualem E TilahunRichard A Goldsby
Dec 1, 2013·Microbiology Spectrum·Bettina C Fries, Avanish K Varshney
Mar 13, 2019·Journal of the American Society for Mass Spectrometry·William R A WichertNicholas E Manicke
Jun 7, 2005·Advanced Drug Delivery Reviews·Nicholas J Mantis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.